Sign in
CompletedPhase 2

A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract

Key facts

Who runs it
Helwan University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
83 people enrolled
Started
10 Jan 2023
Ended
15 Aug 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Fermented Deglycyrrhizinated Licorice
  • Non-fermented Deglycyrrhizinated Licorice
Record updated
29 August 2025

Who can take part

Age
15 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Confirmed diagnosis of Type 1 or Type 2 diabetes mellitus
  • Age between 15 and 65 years
  • Diabetes duration of 1-5 years
  • Body Mass Index (BMI) < 30 kg/m²
  • HbA1c < 9%
  • Serum creatinine < 2mg/dL
  • Serum α-amylase < 45 IU/L (reference range: 28-100 IU/L)
  • Vibration Perception Threshold (VPT) > 15V
  • Absence of clinical symptoms of diabetic polyneuropathy

Who cannot take part

  • Treatment with medications that might influence nerve function (antiepileptic agents, tricyclic antidepressants, sympathomimetic agents)
  • Presence of malignancies
  • Presence of myopathies
  • Presence of neuropathies from other causes
  • Clinical symptoms of diabetic polyneuropathy
  • Inability to comply with study protocol

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This double-blind, placebo-controlled study evaluated the efficacy of oral α-amylase enzyme replacement therapy in treating early-stage diabetic polyneuropathy (DPN). The study was conducted at Al-Azhar University Hospitals with 83 diabetic patients randomized to receive either fermented deglycyrrhizinated licorice extract (FDGL) containing α-amylase enzyme (2500 IU/gm) or placebo for 6 months. Primary outcomes measured improvements in nerve conduction velocity and vibration perception threshold.

The 2 groups in the trial

  • Fermented Deglycyrrhizinated LicoriceExisting treatment, for comparison

    Oral capsules containing 500 mg of fermented deglycyrrhizinated licorice root extract standardized to 2500 IU/gm of α-amylase enzyme and naturally occurring flavonoids and acid-lipase. Administered twice daily (1000 mg/day).

  • Placebo ComparatorPlacebo, for comparison

    500 mg non-fermented deglycyrrhizinated licorice root extract capsules, matching FDGL in appearance, color, weight, and excipients. Administered twice daily.

    Treatment: Non-fermented Deglycyrrhizinated Licorice

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Oral α-Amylase Enzyme Replacement for the Treatment of Diabetic Polyneuropathy
Publications
Record updated
29 August 2025